| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/ANNONC/MDF170 |
| P698 | PubMed publication ID | 12075738 |
| P2093 | author name string | C Fiorentini | |
| G Martinelli | |||
| D Cardinale | |||
| M Civelli | |||
| M T Sandri | |||
| S Cinieri | |||
| G Lamantia | |||
| C M Cipolla | |||
| A Martinoni | |||
| E Borghini | |||
| P433 | issue | 5 | |
| P921 | main subject | breast cancer | Q128581 |
| chemotherapy | Q974135 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 710-715 | |
| P577 | publication date | 2002-05-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy | |
| P478 | volume | 13 |
| Q33531344 | 'Pragmatic randomized controlled trial of individually prescribed exercise versus usual care in a heterogeneous cancer survivor population': a feasibility study PEACH trial: prescribed exercise after chemotherapy |
| Q42706225 | An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity |
| Q39089348 | Analysis of the costs and quality of cardiovascular care in oncological monitoring |
| Q37694541 | Anthracycline Chemotherapy and Cardiotoxicity. |
| Q36624983 | Anthracycline cardiotoxicity |
| Q34639876 | Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment |
| Q38727423 | Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker? |
| Q38542462 | Anthracycline-Induced Cardiomyopathy in Adults |
| Q51319986 | Anthracycline-induced cardiotoxicity: cardiac monitoring by continuous wave-Doppler ultrasound cardiac output monitoring and correlation to echocardiography. |
| Q33896047 | Assessment of cardiotoxicity with cardiac biomarkers in cancer patients |
| Q38015746 | Biological drugs: classic adverse effects and new clinical evidences |
| Q61454620 | Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity |
| Q38362383 | Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity |
| Q38025824 | Cancer drugs and the heart: importance and management |
| Q36887091 | Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. |
| Q38632789 | Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity |
| Q89759750 | Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis |
| Q51739297 | Cardiac complications of chemotherapy: role of biomarkers. |
| Q38091377 | Cardiac toxicity of anticancer agents |
| Q34550487 | Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardioprotection |
| Q38657849 | Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts |
| Q30471284 | Cardio-oncology: a new medical issue |
| Q38551766 | Cardio-oncology: an ongoing evolution. |
| Q39185620 | Cardio-oncology: the Nuclear Option |
| Q43807501 | Cardiotoxicity After Anthracycline Treatment in Survivors of Adult Cancers: Monitoring by USCOM, Echocardiography and Serum Biomarkers |
| Q98736030 | Cardiotoxicity by Anthracycline Regimen Chemotherapy Prolonged T Peak to T End Interval |
| Q38508938 | Cardiotoxicity due to Chemotherapy: the Role of Biomarkers |
| Q91650757 | Cardiotoxicity of Anthracyclines |
| Q26766063 | Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management |
| Q37788952 | Cardiotoxicity of anticancer treatments: what the cardiologist needs to know |
| Q38225977 | Cardiotoxicity of antineoplastic agents: what is the present and future role for imaging? |
| Q45073135 | Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. |
| Q52677836 | Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. |
| Q34604429 | Cardiovascular disease after cancer therapy |
| Q37213203 | Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training |
| Q54959206 | Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress. |
| Q37701713 | Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients |
| Q36582822 | Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort |
| Q35019658 | Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. |
| Q33816471 | Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients |
| Q38559474 | Current and emerging modalities for detection of cardiotoxicity in cardio-oncology |
| Q38845535 | Current views on anthracycline cardiotoxicity. |
| Q90343457 | Cytotoxic-induced heart failure among breast cancer patients in Nigeria: A call to prevent today's cancer patients from being tomorrow's cardiac patients |
| Q33565936 | Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction |
| Q44849977 | Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. |
| Q37822734 | Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer? |
| Q37704467 | Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes |
| Q92677814 | Doxorubicin-Induced Cardiomyopathy in Children |
| Q42706690 | Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion |
| Q37993439 | Early detection of chemotherapy-related left ventricular dysfunction |
| Q36894836 | Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial |
| Q64100654 | Effects of Calorie Restriction and Voluntary Exercise on Doxorubicin-Induced Cardiotoxicity |
| Q55262271 | Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer. |
| Q90202998 | Elevated Cardiac Troponin in Clinical Scenarios Beyond Obstructive Coronary Artery Disease |
| Q50355427 | Evaluation of QTc Interval Prolongation in Breast Cancer Patients after Treatment with Epirubicin, Cyclophosphamide, and Docetaxel and the Influence of Interobserver Variation. |
| Q26785410 | Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors |
| Q37372203 | Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk |
| Q26740352 | Heart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference? |
| Q36523260 | Heart failure induced by non-cardiac drugs |
| Q48244270 | High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. |
| Q39632536 | High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study |
| Q38551772 | Identifying cancer patients at risk for cardiotoxicity |
| Q37076391 | Increased troponin levels in nonischemic cardiac conditions and noncardiac diseases |
| Q88008688 | Left Ventricular Dysfunction and Chemotherapeutic Agents |
| Q89707927 | Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis |
| Q38982319 | Left ventricular ejection fraction in advanced cancer patients: a valuable prognostic tool? |
| Q89800752 | Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls |
| Q30461441 | Management of chemotherapy induced cardiomyopathy |
| Q86805028 | Managing cardiotoxicity of chemotherapy |
| Q36410651 | Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer |
| Q34205189 | Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin |
| Q52577546 | Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. |
| Q50079226 | Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens |
| Q64245417 | Physiopathology and diagnosis of cardiotoxicity in patients submitted to chemotherapy treatment |
| Q36093883 | Pitfalls and problems of relying on serum troponin |
| Q33386386 | Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy |
| Q38786052 | Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments |
| Q57113998 | Priorities in the Cardiovascular Care of Breast Cancer Survivors |
| Q34466688 | Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy |
| Q59478893 | Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic |
| Q28087776 | Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs |
| Q38237495 | Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway |
| Q35872865 | S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers |
| Q27007849 | Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients |
| Q35571721 | Side Effects of Ifosfamide |
| Q38551776 | Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers |
| Q97544688 | The Role of Biomarkers in Cardio-Oncology |
| Q26743433 | The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy |
| Q61454606 | The breast cancer patient in the cardioncology unit |
| Q92582766 | The cardiotoxicity effect of different chemotherapeutic regimens in Iraqi patients with breast cancer: A follow up study |
| Q52982588 | The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. |
| Q100418466 | The role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and Cardio-Oncology Council of the European Society of Cardiology |
| Q53238572 | The value of echocardiography versus cardiac troponin I levels in the early detection of anthracycline cardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up. |
| Q37271427 | Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy |
| Q33647686 | Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation |
| Q54705428 | Trastuzumab-related cardiac events in the treatment of early breast cancer. |
| Q60638396 | Troponin I Provides Insight Into Cardiotoxicity and the Anthracycline-Trastuzumab Interaction |
| Q35834621 | Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy |
| Q37071685 | Troponin in hematologic oncology |
| Q91266299 | Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis |
| Q27027354 | Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity |
| Q80488535 | Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults |
| Q39018351 | Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy |
| Q38069202 | Using cardiac biomarkers and treating cardiotoxicity in cancer |
| Q35588736 | Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy |
Search more.